| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 85 | |||
| Prepaid expenses | 0 | |||
| Other current assets | 0 | |||
| Total current assets | 85 | |||
| Property and equipment, gross | 714 | |||
| Less accumulated depreciation | 25 | |||
| Property and equipment, net | 689 | |||
| Total assets | 774 | |||
| Accounts payable | 4,288 | |||
| Accrued expenses | 1,266 | |||
| Promissory notes | 4,478 | |||
| Total current liabilities | 10,032 | |||
| Related party loan | 5,335 | |||
| Total liabilities | 15,367 | |||
| Preferred stock, 0.0001 par value, 45,000,000 shares authorized as of september 30, 2025 and december 31, 2024 5,423,606 and no shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1 | |||
| Common stock, 0.0001 par value, 740,000,000 and 200,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 229,740,978 and 200,000,000 issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 23 | |||
| Additional paid-in capital | 255,025 | |||
| Accumulated deficit | -269,642 | |||
| Total stockholders' deficit | -14,593 | |||
| Total liabilities and stockholders' deficit | 774 | |||
Semnur Pharmaceuticals, Inc. (SMNRW)
Semnur Pharmaceuticals, Inc. (SMNRW)